Issue 6/2020
Content (9 Articles)
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
Cornelis Smit, Mariska Y. M. Peeters, John N. van den Anker, Catherijne A. J. Knibbe
An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults
Abdullah Aljutayli, Amélie Marsot, Fahima Nekka
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies
Mohamed Elmeliegy, Manoli Vourvahis, Cen Guo, Diane D. Wang
Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine
Chantal A. A. Heppolette, Derek Brunnen, Sohail Bampoe, Peter M. Odor
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
Bola Tayo, Lesley Taylor, Farhad Sahebkar, Gilmour Morrison
Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8
Michel Tod, Laurent Bourguignon, Nathalie Bleyzac, Sylvain Goutelle
Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation
Maaike A. Sikma, Erik M. Van Maarseveen, Claudine C. Hunault, Javier M. Moreno, Ed A. Van de Graaf, Johannes H. Kirkels, Marianne C. Verhaar, Jan C. Grutters, Jozef Kesecioglu, Dylan W. De Lange, Alwin D. R. Huitema
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions
Xia Li, Sebastian Frechen, Daniel Moj, Thorsten Lehr, Max Taubert, Chih-hsuan Hsin, Gerd Mikus, Pertti J. Neuvonen, Klaus T. Olkkola, Teijo I. Saari, Uwe Fuhr
Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis
Laura Maria Fuhr, Nina Hanke, Bernd Meibohm, Thorsten Lehr